ArticleDermatology and therapy2026

Tildrakizumab Improves Disease Severity and Patient-Reported Outcomes in Moderate-to-Severe Chronic Plaque Psoriasis: A Prospective Real-World Study.

Paola Facheris et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.